Voxtalisib
CAY-30323-50 50 mg
Data Sheet: 
SDS:
SDS:
CAS
934493-76-2
Formulation
A crystalline solid
Purity
≥98%
MW
270,2901
Shipment
-20
Long Term Storage
-20
Shelf Life
1460
Description
A dual inhibitor of PI3K and mTORC (IC50s = 9, 110, 43, 9, 160, and 910 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, mTORC1, and mTORC2, respectively); is selective for these kinases over VPS34 (IC50 = 9,100 nM) and a panel of 130 additional protein kinases at 1.5 µM but does inhibit DNAPK (IC50 = 150 nM); decreases EGF-induced PIP3 production in PC3 prostate cancer cells (IC50 = 290 nM); reduces Akt and S6RP phosphorylation in the same model (IC50s = 250 and 120 nM, respectively); inhibits proliferation and colony formation of PC3 cells (IC50s = 1,800 and 270 nM, respectively); reduces tumor growth and increases survival in a GBM-39 mouse xenograft model at 30 mg/kg twice per day either alone or in combination with temozolomide
ESCLUSIVAMENTE PER USO DI RICERCA (RUO) e non per uso terapeutico o diagnostico su uomini o animali. Il prodotto NON è un Dispositivo Medico o un Diagnostico in Vitro.
PRODUCT FOR RESEARCH USE ONLY (RUO) and not for therapeutic or diagnostic use on humans or animals. The product is NOT a Medical Device or an In-Vitro Diagnostic (IVD).
